Cleveland Precision Medicine Chronic Kidney Disease Cohort

目标.克利夫兰慢性肾脏病招募中心（CLE-CKD-RS）已成为KPMP的成员 自5年前成立以来，将继续招募患有糖尿病肾病的CKD患者队列 (DKD)和高血压所致CKD（H-CKD），建立在我们已证明的成功基础上。满足我们 根据拟议的招募目标，我们将把患者筛查范围扩大到克利夫兰诊所主校区 在区域设施中建立了一个医疗诊所和慢性肾病诊所，重点是为少数族裔社区服务的地点。该CLE- CKD-RS将加强和扩大与不同社区的关系，以促进信任并确保 克利夫兰KPMP队列反映了肾脏疾病负担最重的人群。 背景肾脏疾病是常见的，昂贵的和致命的。肾脏精准医学项目（KPMP） 正在建立一个资源，它将有病人水平的临床数据集和分子表型，以识别隐藏的， 肾脏疾病患者的临床可行亚组，用于发现机制，生物标志物和 新疗法KPMP假设提出了多维患者数据、组学水平 分子数据和基因组序列的变异将产生必要的创新工具。 CLE-CKD-RS：与KPMP的协同作用和价值。在第一个资助周期中，CLE-CKD-RS研究团队 成功执行KPMP方案，以伦理和安全的方式招募、活检和保留KPMP的多样化队列 参与者此外，CLE-CKD-RS还成立了一个社区咨询委员会， 有机会教育医疗和患者社区了解KPMP，肾脏疾病的负担 以及促进肾脏健康的方法。虽然KPMP活动首先暂停，然后放缓， 公共卫生应对COVID大流行，CLE-CKD-RS使用远程医疗工具跟踪我们的队列 并在允许的情况下迅速恢复活动。这一经验为未来的黑天鹅事件做好了准备。 CLE-CKD-RS团队的成员作为成员和领导者在KPMP工作组和委员会中任职。 我们参与了两项由机会池基金资助的CKD扩展临床表型研究， 通过赢得机会池资金，吸引其他当地调查小组加入KPMP。基础上 鉴于这些成就，我们提出以下几个重要目标： 1.每年从符合条件的H-CKD患者中安全、道德地收集30-40份研究性肾活检样本 或DKD，5年资助期的目标总入组人数为180名CKD受试者。 2.在整个资助周期内，在研究随访和活动中保留90%的注册参与者。 3.在为黑人和西班牙裔社区服务的区域中心的CKD诊所启动KPMP招募 分别在第6年和第7年进行征聘，并在供资周期内保持在这些地点进行征聘。 4.亲自参加，扩大虚拟和现场社区参与活动，以促进教育和互惠 关于肾脏健康，KPMP参与和一般生物医学研究的相互作用。

Goals. The Cleveland Chronic Kidney Disease Recruiting Site (CLE-CKD-RS) has been a member of the KPMP since its inception 5 years ago and will continue to recruit a cohort of CKD patients with diabetic kidney disease (DKD) and hypertension-attributable CKD (H-CKD), building on our demonstrated successes. To meet our proposed recruiting targets, we will expand patient screening to the Cleveland Clinic main campus general medicine clinic and CKD clinics in regional facilities, focusing on sites that serve minority communities. The CLE- CKD-RS will strengthen and broaden its relationships with diverse communities to foster trust and ensure the Cleveland KPMP cohort reflects the people most burdened by kidney diseases. Background. Kidney diseases are common, costly and deadly. The Kidney Precision Medicine Project (KPMP) is building a resource, which will have patient-level clinical datasets and molecular phenotypes, to identify hidden, clinically actionable subgroups of people with kidney diseases for discovery of mechanisms, biomarkers and new treatments. The KPMP hypothesizes proposes integration of multidimensional patient data, omic level molecular data and variation in genome sequence will generate tools necessary for needed innovation. CLE-CKD-RS: synergy with and value to KPMP. In the first funding cycle the CLE-CKD-RS research team has successfully executed KPMP protocols to ethically and safely enroll, biopsy and retain a diverse cohort of KPMP participants. In addition, The CLE-CKD-RS has established an engaged Community Advisory Board and used opportunities to educate the medical and patient communities about the KPMP, the burden of kidney diseases and approaches to promote kidney health. Although KPMP activities were first suspended and then slowed by the public health response to the COVID pandemic, the CLE-CKD-RS used telehealth tools to follow our cohort and rapidly restarted activities when permitted. This experience has prepared for future black swan events. Members of the CLE-CKD-RS team serve on KPMP working groups and committees as members and leaders. We participate in two CKD extended clinical phenotyping studies funded by the Opportunity Pool funds and engaged other local investigative groups to join the KPMP by winning Opportunity Pool funding. Building upon these successes, we are proposing the following Milestones: 1. Safely and ethically collect 30-40 research kidney biopsies per year from eligible individuals with H-CKD or DKD with target aggregate enrollment of 180 CKD participants for the 5 year funding period. 2. Retain 90% of enrolled participants in research follow-up visits and activities throughout the funding cycle. 3. Initiate KPMP recruitment at CKD clinics in regional sites that serve the Black and Hispanic communities in years 6 and 7, respectively and maintain recruitment at those sites for the duration of the funding cycle. 4. Broaden in person, expand virtual and live community engagement activities for education and reciprocal interactions about kidney health, KPMP participation and biomedical research in general.